Cytokinetics Stock Analysis

CYTK
 Stock
  

USD 51.82  0.68  1.30%   

The recent price surge of Cytokinetics could raise concerns from traders as the firm is trading at a share price of 51.82 on 3,140,609 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.0. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cytokinetics partners.
Continue to Trending Equities.
  
The Cytokinetics stock analysis report makes it easy to digest most publicly released information about Cytokinetics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Cytokinetics Stock analysis module also helps to analyze the Cytokinetics price relationship with some important fundamental indicators such as market cap and management efficiency.

Cytokinetics Stock Analysis Notes

About 114.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 3.11. Cytokinetics had not issued any dividends in recent years. The entity had 1:6 split on the 25th of June 2013. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people. For more info on Cytokinetics please contact Robert Blum at 650 624-3000 or go to www.cytokinetics.com.

Cytokinetics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cytokinetics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cytokinetics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cytokinetics is way too risky over 90 days horizon
Cytokinetics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 70.43 M. Net Loss for the year was (215.31 M) with loss before overhead, payroll, taxes, and interest of (89.51 M).
Cytokinetics currently holds about 471.64 M in cash with (142.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.56.
Cytokinetics has a poor financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Exercise or conversion by Edward Kaye of 11428 shares of Cytokinetics subject to Rule 16b-3

Cytokinetics Upcoming and Recent Events

Earnings reports are used by Cytokinetics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cytokinetics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Cytokinetics Largest EPS Surprises

Earnings surprises can significantly impact Cytokinetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-07-29
2015-06-30-0.23-0.27-0.0417 
2019-08-08
2019-06-30-0.5-0.56-0.0612 
2018-04-26
2018-03-31-0.5-0.56-0.0612 
View All Earnings Estimates

Cytokinetics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Cytokinetics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Cytokinetics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Cytokinetics specific information freely available to individual and institutional investors to make a timely investment decision.
4th of August 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
6th of July 2022
Financial Statements and Exhibits. Other Events. Unregistered Sales of Equity Securities. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
24th of June 2022
Other Events
View
17th of June 2022
Other Events
View
16th of June 2022
Other Events
View
13th of June 2022
Other Events
View
27th of May 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
23rd of May 2022
Other Events
View

Cytokinetics Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cytokinetics's market, we take the total number of its shares issued and multiply it by Cytokinetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Cytokinetics Profitablity

Cytokinetics' profitability indicators refer to fundamental financial ratios that showcase Cytokinetics' ability to generate income relative to its revenue or operating costs. If, let's say, Cytokinetics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Cytokinetics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Cytokinetics' profitability requires more research than a typical breakdown of Cytokinetics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(58.61) (63.24) 
Return on Average Assets(0.31) (0.33) 
Return on Average Equity(1.49) (1.53) 
Return on Invested Capital(0.24) (0.27) 
Return on Sales(2.82) (3.05) 

Management Efficiency

The entity has return on total asset (ROA) of (16.94) % which means that it has lost $16.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (120.54) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics management efficiency ratios could be used to measure how well cytokinetics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -63.24. The current Return on Average Assets is estimated to decrease to -0.33. The current Total Liabilities is estimated to increase to about 644.6 M. The current Current Liabilities is estimated to increase to about 77.5 M
Last ReportedProjected for 2022
Book Value per Share 3.17  2.59 
Enterprise Value over EBIT(20.00) (20.53) 
Enterprise Value over EBITDA(20.27) (20.81) 
Price to Book Value 15.68  16.91 
Tangible Assets Book Value per Share 10.94  8.75 
Enterprise ValueB4.3 B
Tangible Asset Value841.3 M907.7 M

Technical Drivers

As of the 10th of August, Cytokinetics shows the Downside Deviation of 5.79, risk adjusted performance of 0.138, and Mean Deviation of 3.72. Cytokinetics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Cytokinetics, which can be compared to its rivals. Please confirm Cytokinetics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Cytokinetics is priced correctly, providing market reflects its regular price of 51.82 per share. Given that Cytokinetics has jensen alpha of 0.5411, we suggest you to validate Cytokinetics's prevailing market performance to make sure the company can sustain itself at a future point.

Cytokinetics Price Movement Analysis

Execute Study
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cytokinetics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cytokinetics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Cytokinetics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytokinetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytokinetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytokinetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edward Kaye 2 days ago via Macroaxis 
Exercise or conversion by Edward Kaye of 11428 shares of Cytokinetics subject to Rule 16b-3
Robert Blum six days ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over two weeks ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Fady Malik over three weeks ago via Macroaxis 
Exercise or conversion by Fady Malik of 21500 shares of Cytokinetics subject to Rule 16b-3
Bhanji Muna over three weeks ago via Macroaxis 
Acquisition by Bhanji Muna of 274 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over a month ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Fady Malik over two months ago via Macroaxis 
Exercise or conversion by Fady Malik of 21500 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over two months ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over two months ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Fady Malik over two months ago via Macroaxis 
Exercise or conversion by Fady Malik of 13987 shares of Cytokinetics subject to Rule 16b-3
Harrington Robert Arthur over three months ago via Macroaxis 
Acquisition by Harrington Robert Arthur of 10000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over three months ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3

Cytokinetics Technical and Predictive Indicators

Cytokinetics Forecast Models

Cytokinetics time-series forecasting models is one of many Cytokinetics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cytokinetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Cytokinetics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cytokinetics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cytokinetics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Cytokinetics. By using and applying Cytokinetics Stock analysis, traders can create a robust methodology for identifying Cytokinetics entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 15.81  17.06 
EBITDA Margin(2.79) (3.01) 
Gross Margin 0.90  0.89 
Profit Margin(3.06) (3.30) 
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Current Cytokinetics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cytokinetics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cytokinetics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
54.67Buy12Odds
Cytokinetics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Cytokinetics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cytokinetics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cytokinetics, talking to its executives and customers, or listening to Cytokinetics conference calls.
Cytokinetics Analyst Advice Details

Cytokinetics Stock Analysis Indicators

Cytokinetics stock analysis indicators help investors evaluate how Cytokinetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cytokinetics shares will generate the highest return on investment. By understating and applying Cytokinetics stock analysis, traders can identify Cytokinetics position entry and exit signals to maximize returns.
Fifty Two Week Low29.10
Forward Price Earnings-15.17
Fifty Two Week High54.66
Average Daily Volume Last 10 Day1.57M
Average Daily Volume In Three Month1.36M
Fifty Day Average42.31
Two Hundred Day Average38.77
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.6 B
Quarterly Revenue Growth YOY
30.29
Return On Assets
-0.17
Return On Equity
-3.38
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.